Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amunix Pharmaceuticals, Inc.

http://www.amunix.com/

Latest From Amunix Pharmaceuticals, Inc.

Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success

Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.

Companies Blood & Coagulation Disorders

Sanofi Will Employ Adagene’s Technology For Precision Targeting In Cancer

Sanofi will pay $17.5m up front to license candidates developed with Adagene’s SAFEbody platform, which can mask antibodies, enabling them to reach cancer targets in the tumor microenvironment.

Deals Business Strategies

Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020

Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

Growth Business Strategies

J.P. Morgan Day 2: What's Next For Pharma, From Alzheimer's To Omicron

Daily notebook from the virtual J.P. Morgan Healthcare Conference: Alzheimer's rivals Roche and Lilly address their attempts at a different launch for their anti-amyloid therapies than Biogen's Aduhelm. GSK is buoyed by sotrovimab's efficacy against Omicron, BioNTech looks to the future of mRNA and Sanofi, Amgen and AbbVie defend their growth strategies. 

BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Index Ventures
    • Versartis Inc.
    • Diartis Pharmaceuticals, Inc.
UsernamePublicRestriction

Register